Entering the EU skincare market is a documentation exercise, not an approval process. No EU authority pre-approves a cosmetic formula; instead, four pieces of paperwork must be in place before the first batch ships: a Responsible Person (RP) established in the EU, a notification through the Cosmetic Products Notification Portal (CPNP), a Cosmetic Product Safety Report (CPSR), and a Product Information File (PIF) kept for ten years after the last batch is placed on the market. Miss one and the exposure runs from fines to forced delisting. Here is how the pieces fit.
What are the four building blocks of EU market entry?
EU market entry rests on four building blocks: the Responsible Person, the CPNP notification, the CPSR and the PIF. They are often discussed as one package, but they have different owners and different clocks — confusing them is where first-time entrants lose weeks.
| Building block | What it is | Who owns it | Timing |
|---|---|---|---|
| Responsible Person (RP) | A legal entity established in the EU that carries the product’s compliance duties | Your company or an appointed EU representative | Before any market activity |
| CPNP notification | A free notification submitted through the CPNP portal under Article 13 of Regulation (EC) 1223/2009 | The RP | Before the product is placed on the market |
| Cosmetic Product Safety Report (CPSR) | Part A technical information plus Part B, the safety assessor’s conclusions | A qualified safety assessor | Before notification; feeds into the PIF |
| Product Information File (PIF) | The dossier showing the product was developed, assessed and labeled compliantly | Held by or accessible to the RP | Kept for 10 years after the last batch is placed on the market |
The framework runs on notification, not approval: nobody signs off on your serum before launch. What it does instead is place a named, EU-established legal person — the RP — between your product and the authorities. If you are planning a clean beauty line for the EU market, the same four blocks apply; "clean" is a formulation and marketing position, not a separate regulatory track.
Who can act as your EU Responsible Person, and how do non-EU brands appoint one?
The RP must be a legal or natural person established in the EU. A non-EU brand cannot self-declare: it must appoint an EU-based RP through a written mandate — typically a distributor, an importer or a dedicated representative service.
In practice the RP holds or can access the PIF, keeps the notification current, and acts as the contact point for market-surveillance authorities. The RP’s identity does not by itself expose your formula: the role needs product and safety information, not necessarily full know-how, but the scope of data sharing belongs in the mandate.
Two clauses deserve attention. First, the split of duties: the RP carries legal responsibility for compliance while the brand typically controls the formula, claims and artwork, so the mandate should say who pays when something is corrected. Second, the exit: agree what happens to the PIF and the notification if you change RP — a notification pointing at a departed representative is a compliance gap.
When does the CPNP notification happen, and what does it cover?
The RP submits the notification before the product is placed on the EU market — not after launch, and not once the first order lands. The submission is free, and one notification covers the whole EU: no per-country refiling.
The notification covers the product category, name, RP details, the formula framing including any nanomaterials, label artwork and the member states of first placement. Because the notified name must match the label, late artwork changes can force a correction — one reason label finalization sits on the critical path.
Two notes. If the formula contains nanomaterials, Article 16 requires a separate notification six months before placing on the market; under the official interpretation, nanomaterials used as colorants, UV filters or preservatives are exempt from that notification but still must be declared in the Article 13 submission. Do not extrapolate beyond that wording. The US takes a different route under MoCRA — our guide on entering the US skincare market maps the difference.
What goes into the PIF, and why is it kept for 10 years?
The PIF is the evidence file behind the product: the CPSR, a GMP (ISO 22716) declaration of conformity, the evidence behind efficacy claims, and animal-testing data where the applicable rules require it. It is kept for ten years from the date the last batch is placed on the market.
The CPSR has two parts. Part A assembles the technical information — formula, impurities, stability picture, safety data for each ingredient at its use level. Part B is the safety assessor’s conclusion, signed by an assessor with a pharmacist, toxicologist or medical qualification. Part A handled as a formality is a classic failure: the assessor can only conclude on what Part A documents, so thin ingredient data surfaces here as delay.
The ten-year clock runs from the last batch placed on the market, not from first sale or artwork approval, and it continues after discontinuation. That raises two questions for the manufacturing agreement: who holds the PIF and its source data, and what is handed over if the relationship ends. An RP service holding the file while the brand keeps the raw test data works — as long as both sides know who can produce what when an authority asks.
Where do labels and claims most often fail?
The most common market-surveillance findings are mundane: a missing or incorrect RP name and address, a product name that does not match the CPNP notification, and claims the file cannot support. All three are cheap to prevent and expensive to fix after printing.
Label basics are strict. The RP’s name and address must appear on the label, ingredients are listed in INCI descending order, and any printed claim should trace back to evidence in the PIF. Claims such as "dermatologically tested" are not banned, but they are defensible only if the underlying assessment is on file.
On claims, keep the cosmetic lane clear. Cosmetics occupy appearance, sensory and functional territory — moisturizes, helps improve the look of uneven tone, supports the skin’s barrier — while medical efficacy language crosses into a different legal category. Promises of medical efficacy against a skin condition are out of scope for a cosmetic and should be caught at artwork review, not after launch.
One live change: Regulation (EU) 2023/1545 extends allergen labeling to certain fragrance ingredients. Leave-on products above 0.001% and rinse-off products above 0.01% of the listed fragrance allergens must be declared — new products from 31 July 2026, existing products from 31 July 2028. If your line is scented, formula, INCI list and artwork move together; our guide on formulating a fragrance-free skincare product covers the other side of that decision.
What is the sequence from contract to launch?
Regulatory work runs in parallel — formulation, packaging and dossier building can overlap — but the order below matters where one output feeds the next.
- Lock the target market, positioning and formula direction; these decisions drive everything downstream.
- Appoint the EU RP and sign the written mandate, including the scope of data sharing and the exit terms.
- Freeze the formula, run sampling, and plan stability work so results land before the dossier closes.
- Build the CPSR: Part A technical information first, then the Part B assessment from a qualified assessor.
- Submit the CPNP notification through the RP before launch; if nanomaterials are involved, check whether the six-month Article 16 route applies.
- Finalize labels and claims: RP name and address, INCI in descending order, and evidence filed for every printed claim.
- Produce the first batch, release quality, and archive the PIF — the ten-year clock starts when the last batch is placed on the market.
- Maintain the file: update the notification when mandated details change, and keep claim evidence current.
The largest schedule risk is usually not the notification, a same-week task once the inputs exist. It is the dossier inputs: stability results, ingredient data and claim substantiation that arrive late because they started late. Other regions run similar patterns with different paperwork; the Japan and Latin American market guides break down those variations.
If your team is mapping this path for a specific line, our regulatory and formulation teams can review the RP arrangement, dossier inputs and claim list against your target market before artwork is finalized — share the product concept and timeline, and we will flag sequencing risks early.